Estrella Immunopharma, INC. (ESLAW) — SEC Filings

Overview

Estrella Immunopharma, INC. (ESLAW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1 filed on Dec 22, 2025: Estrella Immunopharma, Inc. (ESLAW) is a clinical-stage biopharmaceutical company focused on T-cell therapies for cancer and autoimmune diseases. The company reported consolidated net losses of approximately $4.8 million for the three months ended September 30, 2025, and $12.5 million for the nine m

Sentiment Summary

Across 34 filings, the sentiment breakdown is: 6 bearish, 28 neutral. The dominant filing sentiment for Estrella Immunopharma, INC. is neutral.

Filing Type Overview

Estrella Immunopharma, INC. (ESLAW) has filed 1 S-1, 24 8-K, 6 10-Q, 1 8-K/A, 1 10-K/A, 1 10-K with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (34)

• Estrella Immunopharma Registers 2.5M Shares for Resale Amid Rising Losses — S-1 · Dec 22, 2025 Risk: high
  Estrella Immunopharma, Inc. (ESLAW) is a clinical-stage biopharmaceutical company focused on T-cell therapies for cancer and autoimmune diseases. The company re
• Estrella Immunopharma Files 8-K — 8-K · Dec 4, 2025 Risk: low
  On December 4, 2025, Estrella Immunopharma, Inc. filed an 8-K report. The filing indicates the company's fiscal year ends on December 31st and provides its busi
• Estrella Immunopharma's Net Loss Widens 59.6% Amid R&D Surge — 10-Q · Nov 12, 2025 Risk: high
  Estrella Immunopharma, Inc. (ESLAW) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching approximately $12.45 mill
• 8-K Filing — 8-K · Nov 6, 2025
• Estrella Immunopharma Files 8-K for Other Events — 8-K · Sep 29, 2025 Risk: low
  Estrella Immunopharma, Inc. filed an 8-K on September 29, 2025, reporting an event that occurred on September 23, 2025. The filing is related to "Other Events"
• Estrella Immunopharma Reports Director/Officer Changes — 8-K · Sep 26, 2025 Risk: medium
  Estrella Immunopharma, Inc. filed an 8-K on September 26, 2025, reporting events as of September 22, 2025. The filing indicates a departure of directors or cert
• Estrella Immunopharma's Net Loss Widens 73% Amid R&D Surge — 10-Q · Aug 12, 2025 Risk: high
  Estrella Immunopharma, Inc. (ESLAW) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $7,649,189, up from $4,420,602
• Estrella Immunopharma Faces Delisting Concerns — 8-K · Aug 7, 2025 Risk: high
  Estrella Immunopharma, Inc. filed an 8-K on August 7, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the
• Estrella Immunopharma Files 8-K — 8-K · Jun 5, 2025 Risk: low
  Estrella Immunopharma, Inc. filed an 8-K on June 5, 2025, reporting other events and financial statements. The company, formerly known as TradeUP Acquisition Co
• Estrella Immunopharma Files 8-K on Key Agreements — 8-K · Jun 3, 2025 Risk: medium
  Estrella Immunopharma, Inc. filed an 8-K on June 3, 2025, reporting on events as of May 30, 2025. The filing indicates an entry into a material definitive agree
• Estrella Immunopharma Files 8-K — 8-K · May 29, 2025 Risk: low
  Estrella Immunopharma, Inc. filed an 8-K on May 29, 2025, reporting other events and financial statements. The company, formerly known as TradeUP Acquisition Co
• Estrella Immunopharma Files Q1 2025 10-Q — 10-Q · May 14, 2025 Risk: low
  Estrella Immunopharma, Inc. filed its quarterly report for the period ended March 31, 2025. The company, formerly known as TradeUP Acquisition Corp., is focused
• Estrella Immunopharma Faces Delisting Concerns — 8-K · May 2, 2025 Risk: high
  Estrella Immunopharma, Inc. filed an 8-K on May 2, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of April
• Estrella Immunopharma Files 8-K — 8-K · Feb 21, 2025 Risk: low
  Estrella Immunopharma, Inc. filed an 8-K on February 21, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The company, formerly known as
• Estrella Immunopharma Files 8-K — 8-K · Feb 20, 2025 Risk: medium
  Estrella Immunopharma, Inc. filed an 8-K on February 20, 2025, reporting an event on February 19, 2025. The filing indicates a change in the company's structure
• Estrella Immunopharma Files 8-K: Other Event Reported — 8-K · Dec 16, 2024 Risk: medium
  Estrella Immunopharma, Inc. filed an 8-K on December 16, 2024, reporting an "Other Event." The filing does not contain specific details about the event, dollar
• Estrella Immunopharma Files 8-K on Material Agreement — 8-K · Dec 6, 2024 Risk: medium
  Estrella Immunopharma, Inc. filed an 8-K on December 6, 2024, reporting a material definitive agreement entered into on December 4, 2024. The filing also includ
• Estrella Immunopharma Changes Fiscal Year End — 8-K · Nov 26, 2024 Risk: low
  Estrella Immunopharma, Inc. filed an 8-K on November 26, 2024, reporting a change in its fiscal year end to December 31st. The company, formerly known as TradeU
• Estrella Immunopharma Faces Delisting Notice — 8-K · Nov 25, 2024 Risk: high
  Estrella Immunopharma, Inc. filed an 8-K on November 25, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company, form
• Estrella Immunopharma Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: low
  Estrella Immunopharma, Inc. filed its 10-Q for the quarterly period ended September 30, 2024. The company, formerly known as TradeUP Acquisition Corp. until Feb
• Estrella Immunopharma Files 8-K/A for Officer Departures & Director Changes — 8-K/A · Nov 7, 2024 Risk: medium
  Estrella Immunopharma, Inc. filed an amendment (8-K/A) on November 7, 2024, to its Form 8-K dated August 14, 2024. This amendment primarily addresses the depart
• Estrella Immunopharma Files 10-K/A Amendment — 10-K/A · Oct 28, 2024 Risk: low
  Estrella Immunopharma, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended June 30, 2024. The company, formerly known as TradeUP Acq
• Estrella Immunopharma Files 2024 Annual Report — 10-K · Sep 27, 2024 Risk: low
  Estrella Immunopharma, Inc. filed its annual report for the fiscal year ended June 30, 2024. The company, formerly known as TradeUP Acquisition Corp., is focuse
• Estrella Immunopharma Appoints New CMO & CSO, CMO Departs — 8-K · Aug 20, 2024 Risk: medium
  Estrella Immunopharma, Inc. announced on August 14, 2024, the appointment of Dr. Jianjun Liu as Chief Medical Officer and Dr. Hongbo Li as Chief Scientific Offi
• Estrella Immunopharma Files 8-K with Financials — 8-K · Aug 6, 2024 Risk: medium
  Estrella Immunopharma, Inc. filed an 8-K on August 6, 2024, reporting events as of July 31, 2024. The filing includes financial statements and exhibits, and det
• Estrella Immunopharma Files 8-K with Financials — 8-K · Jul 2, 2024 Risk: low
  Estrella Immunopharma, Inc. filed an 8-K on July 2, 2024, reporting events that occurred on June 26, 2024. The filing includes financial statements and exhibits
• Estrella Immunopharma, Inc. Files 10-Q for Period Ended March 31, 2024 — 10-Q · May 15, 2024 Risk: low
  Estrella Immunopharma, Inc. (ESLAW) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Estrella Immunopharma, Inc. filed a 10-Q report for the quarte
• Estrella Immunopharma Files 8-K for Material Agreement — 8-K · May 13, 2024 Risk: medium
  Estrella Immunopharma, Inc. filed an 8-K on May 13, 2024, reporting the entry into a material definitive agreement and filing financial statements and exhibits.
• Estrella Immunopharma Files 8-K — 8-K · Apr 10, 2024 Risk: low
  Estrella Immunopharma, Inc. filed an 8-K on April 10, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly kn
• Estrella Immunopharma Files 8-K — 8-K · Mar 11, 2024 Risk: low
  Estrella Immunopharma, Inc. filed an 8-K on March 8, 2024, reporting other events and financial statements. The company, formerly known as TradeUP Acquisition C
• Estrella Immunopharma Files 8-K for Material Agreement — 8-K · Mar 7, 2024 Risk: medium
  Estrella Immunopharma, Inc. filed an 8-K on March 7, 2024, reporting a material definitive agreement and financial statements. The company, formerly known as Tr
• Estrella Immunopharma, Inc. Files 10-Q for Period Ended December 31, 2023 — 10-Q · Feb 14, 2024 Risk: low
  Estrella Immunopharma, Inc. (ESLAW) filed a Quarterly Report (10-Q) with the SEC on February 14, 2024. Estrella Immunopharma, Inc. filed a 10-Q report for the q
• Estrella Immunopharma Changes Certifying Accountant — 8-K · Feb 2, 2024
  Estrella Immunopharma, Inc. (ESLA) announced on January 30, 2024, that it is changing its independent accounting firm. This is a standard procedural update, ind
• Estrella Immunopharma Files Routine 8-K on Jan 30 — 8-K · Jan 30, 2024
  Estrella Immunopharma, Inc. filed an 8-K on January 30, 2024, to report 'Other Events' and 'Financial Statements and Exhibits.' This filing, under SEC File Numb

Risk Profile

Risk Assessment: Of ESLAW's 31 recent filings, 6 were flagged as high-risk, 10 as medium-risk, and 15 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Estrella Immunopharma, INC.'s most recent 10-Q filing (Nov 12, 2025):

• Revenue: $0
• Net Income: $ -12.45M
• EPS: $ -0.34
• Debt-to-Equity: N/A
• Cash Position: $1.63M
• Operating Margin: N/A
• Total Assets: $3.52M
• Total Debt: $13.36M

Key Executives

• Cheng Liu
• Michael J. Blankenship
• Dr. Jianjun Liu
• Dr. Hongbo Li
• Dr. Alexey V. Aleshin

Industry Context

Estrella Immunopharma operates in the highly competitive biopharmaceutical sector, focusing on innovative T-cell therapies for oncology and autoimmune diseases. The industry is characterized by long development cycles, substantial R&D investment, and stringent regulatory oversight. Success hinges on demonstrating clinical efficacy and safety, securing intellectual property, and navigating complex manufacturing and commercialization pathways.

Top Tags

8-K (11) · financials (5) · material-agreement (4) · 10-Q (4) · Biotechnology (3) · name-change (3) · regulatory-filing (3) · delisting (3) · listing-standards (3) · corporate-events (3)

Key Numbers

• Consolidated Net Loss: $4.8M — For the three months ended September 30, 2025, an increase from $3.4M in 2024.
• Accumulated Deficit: $36.4M — As of September 30, 2025, indicating significant historical losses.
• Shares of Common Stock: 2,541,206 — Registered for resale by Selling Stockholders, representing 6.7% of outstanding shares.
• Ownership Stake: 66.9% — Held by Eureka Therapeutics, Inc. in Estrella Immunopharma as of December 1, 2025.
• Closing Price per Share: $1.69 — Of ESLA Common Stock on Nasdaq as of December 19, 2025.
• Net Loss: $12.45M — for the nine months ended September 30, 2025, a 59.6% increase from $7.80M in 2024
• Research and Development Expenses: $10.22M — for the nine months ended September 30, 2025, a 60.2% increase from $6.38M in 2024
• Cash and Cash Equivalents: $1.63M — as of September 30, 2025, an increase from $916,916 at December 31, 2024
• Total Stockholders' (Deficit) Equity: $9.84M — as of September 30, 2025, a significant decline from $143,731 at December 31, 2024
• Proceeds from Common Stock Issuance: $2.4M — received from May 2025 to September 2025
• Equity Line Facility: $50M — available from White Lion for future common stock purchases
• Total Fees for STARLIGHT-1 Milestones: $33.0M — payable to Eureka Therapeutics, Inc. for clinical trial services
• Payments to Eureka: $3.5M — for achieved milestones as of September 30, 2025
• Common Stock Shares Issued: 38,280,870 — as of September 30, 2025, up from 36,680,870 at December 31, 2024
• Total Current Liabilities: $9.08M — Increased from $2.99M at December 31, 2024

Related Companies

ESLA · GILD · NVS

Frequently Asked Questions